Earnings Labs

Flexible Solutions International, Inc. (FSI)

Q2 2024 Earnings Call· Thu, Aug 15, 2024

$6.53

+0.31%

Key Takeaways · AI generated
AI summary not yet generated for this transcript. Generation in progress for older transcripts; check back soon, or browse the full transcript below.

Same-Day

+6.42%

1 Week

+9.43%

1 Month

+28.68%

vs S&P

+27.17%

Transcript

Operator

Operator

Good day, everyone, and welcome to today's Flexible Solutions International Second Quarter 2024 financials. At this time, all participants are in a listen-only mode. [Operator Instructions] Please note, this call is being recorded. [Operator Instructions]. It is now my pleasure to turn the conference over to Dan O'Brien.

Daniel O'Brien

Analyst

Thanks, Madison. Good morning. This is Dan O'Brien, CEO of Flexible Solutions. The safe harbor provision. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively by various factors. Information concerning potential factors that could affect the company is detailed from time-to-time in the company's reports filed with the Securities and Exchange Commission. Welcome to the FSI conference call for Q2 2024. To start, I'd like to discuss our company condition and our product lines, along with what we think might occur in the remainder of 2024. I will comment on our financials in the second part of the speech. The NanoChem division. NCS represents approximately 70% of FSI's revenue. This division makes thermal polyaspartic acid, called TPA for short, a biodegradable polymer with many valuable uses. NCS also manufactures SUN 27 and N Savr 30, which were used to reduce nitrogen fertilizer loss from soil. In 2022, NCS started food-grade toll operations using the spray dryer we installed over the last several years. TPA is used in agriculture to significantly increase crop yield. It acts by slowing the crystal growth between fertilizer ions and other ions in the soil, resulting in the fertilizer remaining available longer for the plants to use. TPA is a biodegradable way of treating oilfield water to prevent pipes from clogging with mineral scale. And TPA is also sold as a biodegradable ingredient in cleaning products, and there's a water treatment chemical. In our food division, our special version of TPA is sold as a liquid stability aid. SUN 27 and N Savr 30…

Operator

Operator

Thank you. [Operator Instructions]. And we will take our first question from Tim Clarkson with Van Clemens.

Tim Clarkson

Analyst

Hey, Dan. This is Tim Clarkson. Hey, you're a pretty amazing guy. I have to admit great things going on. What do you -- I know that you're looking at the chance of getting into this drug business. I mean at this point you've had some discussions. I mean is it more likely you're going to be able to get into it or less likely? Or is it still too soon to know?

Daniel O'Brien

Analyst

It's too soon to predict a date, Tim, and thanks for the compliment. This is a place we're going in the future. We're not going to store that machinery forever. But there's a need for more capital than we have access to in order to move forward in the drug industry. So we will have to save our earnings for several years or find a partner who would like to invest in a structure like an LLC to allow us to move forward. We're going to work on it. We're going to assume that it will take quite some period of time. And while we're waiting and saving and meeting people, we will concentrate on that food and nutrition division that's got very good opportunities as well. The drug ones it's a very big blue sky, but the food and nutrition is blue sky also and far more accessible to us, because we have all the equipment up running in clean rooms operational and making test samples for customers.

Tim Clarkson

Analyst

Right. So I'm just going back to the food business, you're using your specialty chemical expertise that you're bringing from agricultural and into the food end. Is it TPC, is that the chemical that you're using?

Daniel O'Brien

Analyst

TPA.

Tim Clarkson

Analyst

TPA [indiscernible]. And I get everything names confused, letters confused. Anyhow, so the -- and the function -- and the value of that is as a preservative or does it have value in terms of improving flavor? Or is it both?

Daniel O'Brien

Analyst

No. It's a -- it prevents the precipitation of crystals in various fluids from fruit juices to wine to beer. And as a result, it reduces the need to chill things down to zero Celsius prior to shipping, which is a big deal. That chilling cost of bringing liquids down to zero and holding it there for two or three days as the stabilization process. We can do that stabilizing with a chemical that does not change anything, a TPA format. And that's a valuable effect or effect for the fruit juice, the wine and the beer industries.

Tim Clarkson

Analyst

Sure. And the FDA has already approved this as a safe additive?

Daniel O'Brien

Analyst

Absolutely. And the EFSA in Europe.

Tim Clarkson

Analyst

Right. Okay. And do you have a name of a company that's going to be providing this so I can sample it? Or is it or is that proprietary at this point?

Daniel O'Brien

Analyst

Its proprietary and won't be released until the other company allows us to. But I would say that, if you were to select a dozen nice wines with a vintage later than 2020 and drank them all, you would definitely have sampled our product.

Tim Clarkson

Analyst

Cool. Cool. And in terms of, I mean, what would be the potential size of this market? Is this a $100 million market or is it too early to know that it too?

Daniel O'Brien

Analyst

It's probably a $7 million to $10 million market for just that one product. But as I mentioned in the speech, we have five more products that are already being test produced and we're waiting for purchase orders.

Tim Clarkson

Analyst

Well, cool. It's very impressive. So, yes, I'd like to at some point visit you out there in Canada. So that's on my list of things to do. So, carry on with the other questions. Thank you.

Daniel O'Brien

Analyst

Thanks, Tim.

Operator

Operator

Thank you. [Operator Instructions]. And we will take our next question from William Gregozeski with Greenridge Global.

William Gregozeski

Analyst · Greenridge Global.

Hey, Dan. Pretty surprised on the Florida LLC sale. Can you kind of talk about why you decided to do that? And then if there's anything you can share about the buyer of that. What their plans are? The press release kind of implied they had big plans for it, if you can give any color on what they're looking at.

Daniel O'Brien

Analyst · Greenridge Global.

Yes. Good morning, Bill. Our decision tree on that was that the greatest value in our relationship was with that group was the exclusive manufacturing and supply agreement, which we've retained. We were and are a wonderful supplier, but we were not particularly adept at helping them find additional customers and close them. It's just not one of our good skill sets. So when a fair price with a significant profit was offered by an executive entering the company who wanted to be a significant owner, When he made a fair and full offer and suggested that his main goal in joining the company was going to be growing the sales, which would then grow our sales to them, it was apparent that we were going to be making a profit, adding sales ability to a customer through allowing a new ownership and not losing anything. So it wasn't a difficult decision.

William Gregozeski

Analyst · Greenridge Global.

Okay. And then any plans for the cash? I know you talked on the last question about the drug business and the line, you need a lot of cash to that. Is there any plan to put it advance or the food business or something else?

Daniel O'Brien

Analyst · Greenridge Global.

At this point, I think we sit back for a little bit. It will get invested at the six month treasury bill rates. And we'll sit back for a little bit and look around because, yes, it will be useful if we move into the drug field, but it's not enough to do the job. So unless you can finish the job, we don't usually start it. So, yes, it's going to be spare capital for the at least the next little bit.

William Gregozeski

Analyst · Greenridge Global.

Okay. On the option grants you mentioned in the prepared remarks, did you say those best at $100 million in revenue per year?

Daniel O'Brien

Analyst · Greenridge Global.

Yes. And very specifically, $100 million, in drug revenue, not they don't get the free ride on our existing revenue.

William Gregozeski

Analyst · Greenridge Global.

Yes. Right, right. Okay. On the gross margins on the existing business, they were up quite a bit. Is that kind of a mid to upper 30s range we can expect going forward or is this more of a quarterly anomaly with just how prices shook out?

Daniel O'Brien

Analyst · Greenridge Global.

I'd have to say that this is a partial anomaly. We go through cycles where we buy very large amounts of product and have to work our way through it. We have to try and raise prices. Sometimes we win, sometimes we lose. But our inventory is now shrinking and we don't know what price our next inventory will be at and what level of success we'll have in matching our inventory prices to our selling prices. This is probably the top end of what we can achieve, but I again product mix is a big thing as well. That was -- the product mix in this quarter was very good in terms of which ones have which margins. And Bill, it's going to change again once we start getting more of the food and nutrition contracts operating and bringing in significant funds. Those have higher margins because of the greater difficulty in operating at food grade levels. So I hate being like this, but it's going to be a moving target somewhere in the range of where we're at now.

William Gregozeski

Analyst · Greenridge Global.

Okay. Okay. And then you mentioned on the Ag business, you've said in the past corn prices are kind of correlated with how your sales are and those have been pretty rough this year. But it sounded like you're seeing some bright spots at least or not as bad maybe for your sales. Is that a fair assessment?

Daniel O'Brien

Analyst · Greenridge Global.

It's a fair assessment and we haven't done badly. I think if you look at our agriculture sales such as we do break them out, which is not much. Our feeling is that it was relatively flat. So our customers are now walking away. They're just not able to push more through the systems. And I think my point about the 2025 early buy season is appropriate. That's when we'll see whether growers have managed to organize their lives so that they can operate and buy the ingredients they want with the crop prices wherever they are. So, I think it's a positive forward look, but not a highly positive one.

William Gregozeski

Analyst · Greenridge Global.

Okay. All right. Great. Thanks, Dan.

Daniel O'Brien

Analyst · Greenridge Global.

Thank you, Bill.

Operator

Operator

Thank you. And it appears that we have no further questions at this time. I will now turn the program back to Dan O'Brien for closing remarks.

Daniel O'Brien

Analyst

Thank you, Madison. Well, I have no closing remarks other than to say looking forward to talking to you all in about three months. Have a good rest of your summer. The call is over.

Operator

Operator

Thank you. This does conclude today's Flexible Solutions International second quarter 2024 financials. Thank you for your participation. You may disconnect at any time.